Is FALL a side effect of SORAFENIB (RAF KINASE INHIBITOR) ? ( FactMed.com )

About this FactMed analysis covering adverse side effect reports of SORAFENIB (RAF KINASE INHIBITOR) patients who developed FALL.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 37 individuals taking SORAFENIB (RAF KINASE INHIBITOR) reported FALL to the FDA. A total of 3329 SORAFENIB (RAF KINASE INHIBITOR) drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between SORAFENIB (RAF KINASE INHIBITOR) and FALL. In doing so, we compare SORAFENIB (RAF KINASE INHIBITOR) with other drugs that cause FALL, to help you evaluate whether or not SORAFENIB (RAF KINASE INHIBITOR) causes FALL. Likewise, this page shows the most highly-reported side effects of SORAFENIB (RAF KINASE INHIBITOR), so you can see if FALL ranks among SORAFENIB (RAF KINASE INHIBITOR)'s most well-known side effects.

Summary Statistics
Reports of SORAFENIB (RAF KINASE INHIBITOR) causing FALL: 37
Reports of any side effect of SORAFENIB (RAF KINASE INHIBITOR) : 3329
Percentage of SORAFENIB (RAF KINASE INHIBITOR) patients where FALL is a reported side effect: 1.1114%

FDA reports of any drug causing FALL : 96231
Average percentage for all medicated patients where FALL is reported as a complication: 0.6031%

Physician opinion on SORAFENIB (RAF KINASE INHIBITOR) as adverse event culprit:

Overall opinion for all reports of this drug:

Most frequent diagnoses/indications for prescribing SORAFENIB (RAF KINASE INHIBITOR):

HEPATIC NEOPLASM MALIGNANT ( 770 patients )
RENAL CELL CARCINOMA ( 114 patients )
THYROID CANCER ( 65 patients )
METASTATIC RENAL CELL CARCINOMA ( 44 patients )
THYROID CANCER METASTATIC ( 35 patients )
BREAST CANCER ( 31 patients )
BREAST CANCER METASTATIC ( 27 patients )
GASTRIC CANCER ( 25 patients )
NON-SMALL CELL LUNG CANCER ( 25 patients )
COLORECTAL CANCER METASTATIC ( 22 patients )
RENAL CANCER ( 17 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 14 patients )
BILE DUCT CANCER ( 14 patients )
SALIVARY GLAND CANCER ( 7 patients )
HEPATIC CANCER METASTATIC ( 7 patients )
COLORECTAL CANCER ( 7 patients )
SMALL CELL LUNG CANCER STAGE UNSPECIFIED ( 6 patients )
RECTAL CANCER ( 5 patients )
PANCREATIC CARCINOMA ( 4 patients )
PROSTATE CANCER ( 4 patients )
INTRAOCULAR MELANOMA ( 4 patients )
HEPATIC NEOPLASM MALIGNANT RECURRENT ( 3 patients )
NEOPLASM ( 3 patients )
LIVER DISORDER ( 3 patients )
ANGIOSARCOMA ( 3 patients )
NON-SMALL CELL LUNG CANCER STAGE IV ( 3 patients )
METASTASES TO LUNG ( 3 patients )
HEPATIC NEOPLASM MALIGNANT NON-RESECTABLE ( 3 patients )
COLORECTAL CANCER STAGE IV ( 3 patients )
NEOPLASM MALIGNANT ( 3 patients )
GALLBLADDER CANCER METASTATIC ( 3 patients )
BILIARY CANCER METASTATIC ( 3 patients )
METASTASIS ( 3 patients )
COLON CANCER METASTATIC ( 2 patients )
HYPOPHARYNGEAL CANCER ( 2 patients )
DESMOID TUMOUR ( 2 patients )
NEUROENDOCRINE CARCINOMA ( 2 patients )
ACUTE MYELOID LEUKAEMIA (IN REMISSION) ( 2 patients )
LUNG NEOPLASM MALIGNANT ( 2 patients )
OESOPHAGEAL CARCINOMA ( 2 patients )
METASTATIC MALIGNANT MELANOMA ( 2 patients )
TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED ( 2 patients )
METASTATIC SQUAMOUS CELL CARCINOMA ( 2 patients )
ANGINA PECTORIS ( 2 patients )
RENAL CELL CARCINOMA STAGE IV ( 2 patients )
OSTEOSARCOMA METASTATIC ( 2 patients )
BONE SARCOMA ( 2 patients )
METASTATIC OCULAR MELANOMA ( 2 patients )
METASTATIC SALIVARY GLAND CANCER ( 2 patients )
TONSIL CANCER ( 2 patients )
MYELODYSPLASTIC SYNDROME ( 1 patients )
PROSTATE CANCER METASTATIC ( 1 patients )
GALLBLADDER CANCER ( 1 patients )
NEUROENDOCRINE TUMOUR ( 1 patients )
MALIGNANT NEOPLASM OF RENAL PELVIS ( 1 patients )
GLIOMA ( 1 patients )
BLADDER CANCER ( 1 patients )
OVARIAN CANCER METASTATIC ( 1 patients )
CAROTID ARTERY DISEASE ( 1 patients )
HEPATOBLASTOMA ( 1 patients )
NASOPHARYNGEAL CANCER ( 1 patients )
ACUTE MYELOID LEUKAEMIA ( 1 patients )
LUNG ADENOCARCINOMA ( 1 patients )
RENAL CANCER METASTATIC ( 1 patients )
DIFFUSE LARGE B-CELL LYMPHOMA ( 1 patients )
NEUROENDOCRINE CARCINOMA OF THE SKIN ( 1 patients )
MALIGNANT HISTIOCYTOSIS ( 1 patients )
ANTICOAGULANT THERAPY ( 1 patients )
MALIGNANT SOFT TISSUE NEOPLASM ( 1 patients )
SARCOMA ( 1 patients )
GERM CELL CANCER ( 1 patients )
OESOPHAGEAL ADENOCARCINOMA ( 1 patients )
SQUAMOUS CELL CARCINOMA ( 1 patients )
HEAD AND NECK CANCER ( 1 patients )
OVARIAN EPITHELIAL CANCER ( 1 patients )
( 0 patients )

Drugs with high FDA adverse event association with FALL:

FOSAMAX (21241 patients)
FORTEO (10645 patients)
AVONEX (9614 patients)
ASPIRIN (8492 patients)
TYSABRI (6333 patients)
VIOXX (5874 patients)
SEROQUEL (3989 patients)
LASIX (3815 patients)
LIPITOR (3765 patients)
NEXIUM (3646 patients)
LYRICA (3421 patients)
SYNTHROID (3306 patients)
ZOMETA (3245 patients)
COUMADIN (3241 patients)
PREDNISONE (3147 patients)
LISINOPRIL (3143 patients)
NEURONTIN (3080 patients)
ALENDRONATE SODIUM (2879 patients)
HUMIRA (2761 patients)
FUROSEMIDE (2740 patients)
VITAMIN D (2726 patients)
SIMVASTATIN (2711 patients)
OMEPRAZOLE (2689 patients)
ATENOLOL (2605 patients)
PLAVIX (2560 patients)
XANAX (2542 patients)
CYMBALTA (2539 patients)
AMBIEN (2516 patients)
FOLIC ACID (2385 patients)
ZOLOFT (2380 patients)
ENBREL (2361 patients)
DIGOXIN (2267 patients)
PRILOSEC (2210 patients)
FOSAMAX PLUS D (2198 patients)
HYDROCHLOROTHIAZIDE (2156 patients)
REBIF (2150 patients)
METHOTREXATE (2147 patients)
CELEBREX (2131 patients)
ZOCOR (2108 patients)
LEVOTHYROXINE SODIUM (2092 patients)
REMICADE (2019 patients)
OXYCONTIN (1990 patients)
CALCIUM (1961 patients)
AREDIA (1952 patients)
ACETAMINOPHEN (1950 patients)
PROTONIX (1922 patients)
NORVASC (1894 patients)
LORAZEPAM (1873 patients)
LEXAPRO (1843 patients)
VICODIN (1842 patients)
LANTUS (1802 patients)
POTASSIUM CHLORIDE (1780 patients)
DURAGESIC-100 (1722 patients)
SANDOSTATIN LAR (1705 patients)
GABAPENTIN (1691 patients)
WARFARIN SODIUM (1649 patients)
ACTONEL (1647 patients)
TOPROL-XL (1619 patients)
DIOVAN (1614 patients)
ALBUTEROL (1580 patients)
CRESTOR (1574 patients)
CALCIUM (UNSPECIFIED) (1539 patients)
EFFEXOR (1519 patients)
PAXIL (1501 patients)
CLONAZEPAM (1497 patients)
PREMARIN (1495 patients)
PREVACID (1490 patients)
PERCOCET (1475 patients)
METFORMIN HCL (1472 patients)
PROZAC (1387 patients)
BONIVA (1381 patients)
ATIVAN (1349 patients)
ALLOPURINOL (1302 patients)
ZYPREXA (1299 patients)
METOPROLOL TARTRATE (1257 patients)
VITAMINS (UNSPECIFIED) (1256 patients)
LEVAQUIN (1244 patients)
REVLIMID (1224 patients)
IBUPROFEN (1219 patients)
CALCIUM CARBONATE (1216 patients)
ADVAIR DISKUS 100/50 (1205 patients)
CLOZARIL (1192 patients)
RISPERDAL (1175 patients)
AMLODIPINE (1165 patients)
DIAZEPAM (1164 patients)
BACLOFEN (1159 patients)
MULTI-VITAMIN (1150 patients)
KLONOPIN (1149 patients)
INSULIN (1136 patients)
ALPRAZOLAM (1130 patients)
BETASERON (1130 patients)
CELEXA (1100 patients)
CITALOPRAM HYDROBROMIDE (1093 patients)
TRAMADOL HCL (1089 patients)
ASCORBIC ACID (1087 patients)
BYETTA (1085 patients)
OXYCODONE HCL (1085 patients)
HUMALOG (1082 patients)
DEXAMETHASONE (1078 patients)
PREDNISONE TAB (1060 patients)
COREG (1057 patients)
VITAMIN E (1029 patients)
MORPHINE (1025 patients)
VALIUM (1015 patients)
NITROGLYCERIN (1013 patients)
MULTI-VITAMINS (1007 patients)
DIANEAL (998 patients)
SPIRONOLACTONE (972 patients)
ZANTAC (966 patients)
WELLBUTRIN (958 patients)
LORTAB (957 patients)
SPIRIVA (952 patients)
SINGULAIR (949 patients)
VITAMIN D (UNSPECIFIED) (946 patients)
TRAZODONE HCL (944 patients)
PREDNISOLONE (941 patients)
CHANTIX (940 patients)
EXELON (938 patients)
ZYRTEC (937 patients)
ZOLEDRONOC ACID (933 patients)
RAMIPRIL (927 patients)
ZOFRAN (894 patients)
METOPROLOL (891 patients)
FLEXERIL (883 patients)
GLUCOPHAGE (879 patients)
EVISTA (874 patients)
ARICEPT (873 patients)
[THERAPY UNSPECIFIED] (871 patients)
FENTANYL (866 patients)
NAMENDA (850 patients)
COZAAR (846 patients)
ACTOS (834 patients)
VITAMIN B-12 (818 patients)
ALLEGRA (816 patients)
ENALAPRIL MALEATE (806 patients)
TEGRETOL (804 patients)
FLOMAX (796 patients)
DECADRON (795 patients)
PRADAXA (784 patients)
TYLENOL (CAPLET) (775 patients)
AMITRIPTYLINE HCL (760 patients)
ZETIA (759 patients)
AMOXICILLIN (756 patients)
LOVENOX (753 patients)
KEPPRA (752 patients)
COLACE (751 patients)
EFFEXOR XR (741 patients)
LAMICTAL (724 patients)
ELAVIL (713 patients)
ALDACTONE (708 patients)
FISH OIL (706 patients)
HYDROCODONE (706 patients)
DEPAKOTE (705 patients)
ULTRAM (703 patients)
EXJADE (691 patients)
DILAUDID (687 patients)
DILANTIN (682 patients)
ARIMIDEX (682 patients)
GLIPIZIDE (681 patients)
AVANDIA (678 patients)
LANSOPRAZOLE (672 patients)
REGLAN (671 patients)
LOPRESSOR (670 patients)
POTASSIUM (668 patients)
GLYBURIDE (663 patients)
MIRTAZAPINE (661 patients)
CLONIDINE (655 patients)
FEMARA (653 patients)
HYDROCODONE BITARTRATE (645 patients)
TRACLEER (644 patients)
TEMAZEPAM (643 patients)
BENADRYL (642 patients)
TYLENOL (642 patients)
TOPAMAX (632 patients)
METFORMIN (632 patients)
ALTACE (630 patients)
MORPHINE SULFATE (627 patients)
FERROUS SULFATE TAB (617 patients)
RANITIDINE (610 patients)
COMPAZINE (609 patients)
HEPARIN SODIUM INJECTION (605 patients)
CIPROFLOXACIN (604 patients)
VELCADE (599 patients)
FLONASE (590 patients)
CLOZAPINE (589 patients)
PEPCID (586 patients)
LEVOXYL (582 patients)
SOMA (582 patients)
TAMOXIFEN CITRATE (573 patients)
PROVIGIL (571 patients)
CARVEDILOL (569 patients)
NAPROXEN (569 patients)
RECLAST (568 patients)
METOPROLOL SUCCINATE (561 patients)
FLUOXETINE (557 patients)
AMARYL (552 patients)
KLOR-CON (551 patients)
ZOLPIDEM (546 patients)
PANTOPRAZOLE (542 patients)
CEPHALEXIN (540 patients)
CLARITIN (540 patients)
CHEMOTHERAPEUTICS NOS (534 patients)
ARANESP (531 patients)
SINEMET (528 patients)
ACIPHEX (526 patients)
REQUIP (524 patients)
VERAPAMIL (521 patients)
PROMETHAZINE (521 patients)
BISOPROLOL FUMARATE (520 patients)
IRON (519 patients)

Most common side effects for patients taking SORAFENIB (RAF KINASE INHIBITOR):

DIARRHOEA (613 patients)
HEPATIC FAILURE (378 patients)
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME (342 patients)
HEPATIC ENCEPHALOPATHY (320 patients)
FATIGUE (300 patients)
RASH (276 patients)
ASCITES (253 patients)
ABDOMINAL PAIN (237 patients)
DECREASED APPETITE (226 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (198 patients)
PYREXIA (191 patients)
ASPARTATE AMINOTRANSFERASE INCREASED (179 patients)
NAUSEA (165 patients)
HYPERTENSION (160 patients)
ASTHENIA (154 patients)
DEHYDRATION (140 patients)
HEPATIC FUNCTION ABNORMAL (133 patients)
DYSPNOEA (131 patients)
CONFUSIONAL STATE (131 patients)
HYPOKALAEMIA (125 patients)
ALOPECIA (124 patients)
VOMITING (118 patients)
CONSTIPATION (115 patients)
INTERSTITIAL LUNG DISEASE (114 patients)
LEFT VENTRICULAR DYSFUNCTION (113 patients)
DEATH (113 patients)
ENDOCARDITIS (112 patients)
ARTHRALGIA (111 patients)
STOMATITIS (111 patients)
ABDOMINAL PAIN UPPER (110 patients)
JAUNDICE (108 patients)
HEPATIC NEOPLASM MALIGNANT (106 patients)
GASTROINTESTINAL HAEMORRHAGE (106 patients)
RETINAL VASCULAR THROMBOSIS (103 patients)
LOWER GASTROINTESTINAL HAEMORRHAGE (103 patients)
LIVER CARCINOMA RUPTURED (101 patients)
OEDEMA PERIPHERAL (97 patients)
PLEURAL EFFUSION (97 patients)
STAPHYLOCOCCAL INFECTION (96 patients)
PNEUMONIA BACTERIAL (96 patients)
ENTEROBACTER INFECTION (96 patients)
MYOPATHY (95 patients)
DRY MOUTH (94 patients)
PAIN IN EXTREMITY (93 patients)
ANXIETY (90 patients)
MALAISE (89 patients)
PULMONARY EMBOLISM (85 patients)
ANAEMIA (84 patients)
PLATELET COUNT DECREASED (81 patients)
BACK PAIN (79 patients)
SEPSIS (78 patients)
PRURITUS (78 patients)
DUODENAL ULCER (77 patients)
MIGRAINE (76 patients)
MITRAL VALVE INCOMPETENCE (76 patients)
HYPOGLYCAEMIA (76 patients)
C-REACTIVE PROTEIN INCREASED (74 patients)
BLOOD PRESSURE INCREASED (73 patients)
VARICES OESOPHAGEAL (73 patients)
HEADACHE (72 patients)
RETINAL VEIN OCCLUSION (72 patients)
ABASIA (69 patients)
RENAL FAILURE ACUTE (69 patients)
WEIGHT DECREASED (67 patients)
DEEP VEIN THROMBOSIS (67 patients)
DIZZINESS (65 patients)
ERYTHEMA (65 patients)
GENERAL PHYSICAL HEALTH DETERIORATION (64 patients)
CONVULSION (63 patients)
ALANINE AMINOTRANSFERASE INCREASED (62 patients)
DYSPHONIA (62 patients)
CEREBRAL HAEMORRHAGE (60 patients)
APHAGIA (58 patients)
COLITIS (58 patients)
PNEUMONIA (57 patients)
GASTRIC ULCER (56 patients)
HYPONATRAEMIA (55 patients)
HAEMOGLOBIN DECREASED (53 patients)
RESPIRATORY FAILURE (52 patients)
LUNG DISORDER (52 patients)
CEREBRAL ISCHAEMIA (49 patients)
PARAESTHESIA (49 patients)
BLOOD BILIRUBIN INCREASED (48 patients)
GAIT DISTURBANCE (48 patients)
THYROID CANCER METASTATIC (44 patients)
DEPRESSED LEVEL OF CONSCIOUSNESS (43 patients)
PERICARDIAL EFFUSION (41 patients)
THROMBOCYTOPENIA (41 patients)
BLISTER (41 patients)
FEBRILE NEUTROPENIA (40 patients)
BLOOD LACTATE DEHYDROGENASE INCREASED (40 patients)
HALLUCINATION (40 patients)
CHILLS (40 patients)
AMMONIA INCREASED (39 patients)
SKIN ULCER (39 patients)
BLOOD ALKALINE PHOSPHATASE INCREASED (38 patients)
PAIN (38 patients)
HYPOALBUMINAEMIA (38 patients)
HYPOCALCAEMIA (37 patients)
FALL (37 patients)
POLLAKIURIA (37 patients)
BLOOD PRESSURE DECREASED (37 patients)
SKIN EXFOLIATION (37 patients)
INSOMNIA (36 patients)
CARDIAC ARREST (36 patients)
HYPOAESTHESIA (35 patients)
INFECTIOUS PERITONITIS (35 patients)
MYOCARDIAL INFARCTION (35 patients)
RETINAL VASCULAR DISORDER (34 patients)
RENAL FAILURE (34 patients)
LIPASE INCREASED (34 patients)
HYPERKALAEMIA (33 patients)
HYPERGLYCAEMIA (33 patients)
HAEMOPTYSIS (31 patients)
ATRIAL FIBRILLATION (30 patients)
GENERALISED OEDEMA (30 patients)
FAECAL INCONTINENCE (30 patients)
WHITE BLOOD CELL COUNT DECREASED (30 patients)
CELLULITIS (29 patients)
CHEST PAIN (29 patients)
SOMNOLENCE (29 patients)
HYPERBILIRUBINAEMIA (28 patients)
HYPOTENSION (28 patients)
MUSCLE SPASMS (28 patients)
ABDOMINAL DISTENSION (27 patients)
WHITE BLOOD CELL COUNT INCREASED (27 patients)
VISION BLURRED (27 patients)
HEPATIC PAIN (26 patients)
BLOOD ALBUMIN DECREASED (26 patients)
DYSURIA (25 patients)
RASH GENERALISED (25 patients)
BLOOD SODIUM DECREASED (25 patients)
BLOOD URIC ACID INCREASED (25 patients)
COMA (25 patients)
COUGH (25 patients)
PANCYTOPENIA (25 patients)
ACUTE ABDOMEN (24 patients)
EOSINOPHIL COUNT INCREASED (24 patients)
CEREBROVASCULAR ACCIDENT (24 patients)
METASTASES TO CENTRAL NERVOUS SYSTEM (23 patients)
CEREBRAL INFARCTION (23 patients)
HYPOMAGNESAEMIA (23 patients)
RETINAL VEIN THROMBOSIS (23 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (23 patients)
TUMOUR LYSIS SYNDROME (22 patients)
HYPOPHOSPHATAEMIA (22 patients)
INFECTION (22 patients)
ORAL PAIN (22 patients)
BLOOD CREATININE INCREASED (22 patients)
NEUTROPENIA (22 patients)
RENAL IMPAIRMENT (22 patients)
LETHARGY (22 patients)
SKIN TOXICITY (21 patients)
TONGUE BLISTERING (21 patients)
LIVER ABSCESS (21 patients)
HAEMATEMESIS (21 patients)
OESOPHAGEAL VARICES HAEMORRHAGE (20 patients)
MENTAL IMPAIRMENT (20 patients)
NERVOUSNESS (20 patients)
NEPHROTIC SYNDROME (20 patients)
HYPOPHAGIA (20 patients)
ADRENAL INSUFFICIENCY (19 patients)
DRY SKIN (19 patients)
BLOOD AMYLASE INCREASED (19 patients)
OEDEMA (19 patients)
INFECTIOUS PLEURAL EFFUSION (19 patients)
DYSPEPSIA (19 patients)
COMA HEPATIC (19 patients)
HEART RATE INCREASED (18 patients)
HYPERTENSIVE CRISIS (18 patients)
MYALGIA (18 patients)
ECZEMA (18 patients)
URINARY TRACT INFECTION (18 patients)
NEUROMYOPATHY (18 patients)
MEDICAL DEVICE COMPLICATION (18 patients)
DIVERTICULITIS (18 patients)
OSTEOMYELITIS (18 patients)
CEREBRAL ATROPHY (18 patients)
CEREBRAL VENTRICLE DILATATION (18 patients)
DIABETIC FOOT INFECTION (18 patients)
NECK PAIN (18 patients)
OLIGURIA (17 patients)
GASTROINTESTINAL DISORDER (17 patients)
HAEMATOCHEZIA (17 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (17 patients)
HYPOTHYROIDISM (17 patients)
TRANSAMINASES INCREASED (17 patients)
OROPHARYNGEAL PAIN (17 patients)
CHRONIC MYELOID LEUKAEMIA (17 patients)
NEOPLASM PROGRESSION (17 patients)
METASTASES TO ADRENALS (16 patients)
LYMPHOCYTE COUNT DECREASED (16 patients)
INTERNATIONAL NORMALISED RATIO INCREASED (16 patients)
MULTI-ORGAN FAILURE (16 patients)
FEAR (16 patients)
PANCREATIC CARCINOMA (16 patients)
HYPERSOMNIA (16 patients)
EPILEPSY (16 patients)
SUBARACHNOID HAEMORRHAGE (16 patients)
METASTASES TO LUNG (16 patients)
TACHYCARDIA (16 patients)
MUSCULAR WEAKNESS (16 patients)
KLEBSIELLA SEPSIS (16 patients)
MYOCARDIAL ISCHAEMIA (16 patients)
DYSGEUSIA (16 patients)
LUNG INFECTION (16 patients)
FAECES DISCOLOURED (16 patients)
PAIN OF SKIN (16 patients)
SPINAL FRACTURE (16 patients)
PANIC REACTION (16 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.

Recent FactMed Activity for SORAFENIB (RAF KINASE INHIBITOR)

Issue	Description / Topic	Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about FALL and SORAFENIB (RAF KINASE INHIBITOR), post it here. You may receive a response from a fellow patient - or a leading expert in the field.

Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking SORAFENIB (RAF KINASE INHIBITOR), post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.

Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in SORAFENIB (RAF KINASE INHIBITOR). This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.

We are currently accepting registration for SORAFENIB (RAF KINASE INHIBITOR) experts. If you are a healthcare provider experienced in prescribing SORAFENIB (RAF KINASE INHIBITOR), please register here.